OpenURL Connection Search - EBSCO

Connecting you to content on EBSCOhost

Select item for more details and to access through your institution.

Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.
Published in:
Alimentary Pharmacology & Therapeutics, 2017, v. 46, n. 3, p. 292, doi. 10.1111/apt.14164
By:
- D'Haens, G. R.;
- Sandborn, W. J.;
- Zou, G.;
- Stitt, L. W.;
- Rutgeerts, P. J.;
- Gilgen, D.;
- Jairath, V.;
- Hindryckx, P.;
- Shackelton, L. M.;
- Vandervoort, M. K.;
- Parker, C. E.;
- Muller, C.;
- Pai, R. K.;
- Levchenko, O.;
- Marakhouski, Y.;
- Horynski, M.;
- Mikhailova, E.;
- Kharchenko, N.;
- Pimanov, S.;
- Feagan, B. G.
Publication type:
Article
Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis.
Published in:
Alimentary Pharmacology & Therapeutics, 2011, v. 33, n. 3, p. 313, doi. 10.1111/j.1365-2036.2010.04537.x
By:
- Kruis, W.;
- Jonaitis, L.;
- Pokrotnieks, J.;
- Mikhailova, T. L.;
- Horynski, M.;
- Bátovský, M.;
- Lozynsky, Y. S.;
- Zakharash, Y.;
- Rácz, I.;
- Kull, K.;
- Vcev, A.;
- Faszczyk, M.;
- Dilger, K.;
- Greinwald, R.;
- Mueller, R.
Publication type:
Article